Pediatric CD56+ anaplastic large cell lymphoma: A review of the literature

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 12, 2006, Pages 1859-1864

  Dunphy, Cherie H ^a   DeMello, Daphne E ^b   Gale, Gordon B ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Cardinal Glennon Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD2 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANZYME B; METHOTREXATE; PREDNISONE; PROTEIN TIA 1; RNA BINDING PROTEIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ANAPLASTIC LARGE CELL LYMPHOMA; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CD4+ T LYMPHOCYTE; CD56+ T LYMPHOCYTE; CD57+ T LYMPHOCYTE; CELL GRANULE; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ADOLESCENT; ANTIGENS, CD56; CHILD; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; MALE;

EID: 33845408467     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:230-235. World Health Organization Classification of Tumours.
2. Kraveka JM, Weinstein HJ, Hutchison RE, et al. Pediatric anaplastic large cell lymphoma: results of a randomized phase III pediatric oncology group trial of APO versus APO + intermediate dose methotrexate/high dose ARA-C (POG #9315) [abstract]. Proceedings of the American Society of Clinical Oncology. 2003;22:795.
3. Akamatsu M, Takeshita M, Ohshima K, Kikachi M. Analysis of adhesion molecules in Ki-1 anaplastic large cell lymphoma. Virchows Archiv. 1994;425: 33-39.
4. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol. 1995;19:284-296.
5. Krenacs L, Wellmann A, Sorbara L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood. 1997;89:980-989.
6. Paulli M, Boveri E, Rosso R, et al. CD56/neural cell adhesion molecule expression in primary extranodal Ki-1/CD30+ lymphoma: report of a pediatric case with simultaneous cutaneous and bone localizations. Am J Dermatopathol. 1997;19:384-390.
7. Chang S-E, Park I-J, Huh J, et al. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma. Br J Dermatol. 2000;142: 766-770.
8. Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC. The expression of TIA-1 + cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol. 1999;30:228-236.
9. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993-3000.
10. Kim HK, Jin S-Y, Lee NS, Won JH, Park HS, Yang WI. Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma. Arch Pathol Lab Med. 2004;128:e96-e99.
11. Gould JW, Eppes RB, Gilliam AC, et al. Solitary primary cutaneous CD30+ large cell lymphoma of natural killer cell phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child. Am J Dermatopathol. 2000;22:422-428.
12. Meech SJ, McGavran L, Odom LF, et al. Unusual childhood extramedullary hematology malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood. 2001;98:1209-1216.
13. Sambrook J, Fritsch EF, Maniatis J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1987.
14. Southern EM. Detection of specific sequences among DNA fragments by gel electrophoresis. J Mol Biol. 1975;87:503-517.
15. Popnikolov NK, Payne DA, Hudnall SD, et al. CD13-positive anaplastic large cell lymphoma of T-cell origin: a diagnostic and histogenetic problem. Arch Pathol Lab Med. 2000;124:1804-1808.
16. Dunphy CH, Gardner LJ, Manes JL, Bee CS, Taysi K. CD30+ anaplastic large cell lymphoma with aberrant expression of CD13: case report and review of the literature. J Clin Lab Anal. 2000;14:299-304.
17. Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003; 119:205-212.
18. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996; 38:4005-4011.
19. Noorali S, Pervez S, Yaqoob N, et al. Prevalence and characterization of anaplastic large cell lymphoma and its association with Epstein-Barr virus in Pakistani patients. Pathol Res Pract. 2004;200:669-679.
20. Loughran TP. CD56+ hematologic malignancies. Leuk Res. 1999;23:675-676.
21. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
22. Kagami Y, Suzuki R, Taji H, et al. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999;23:1184-1200.